Illumina, Inc 8-K, filed Aug 9, 2023
Illumina, Inc. (ILMN)
8-K
2023-08-09
For: 2023-08-07
View Original
Added on
April 12, 2026
About this 8-K
Illumina, Inc filed this 8-K on August 9, 2023, reporting on events of August 7, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2023

(Exact name of registrant as specified in its charter)
(Commission File Number)
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices) (Zip code)
(858 ) 202-4500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 7, 2023, Dr. Phil Febbo, Chief Medical Officer, departed Illumina, Inc. (the “Company”), and on August 9, 2023, the Company announced that Dr. Alex Aravanis, who has served as Chief Technology Officer, will also depart the Company.
A copy of the press release announcing Dr. Aravanis’s departure and the appointment of Dr. Steve Barnard as the Company’s new Chief Technology Officer, effective immediately, is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Illumina, Inc. Press Release, dated August 9, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ILLUMINA, INC. | |||||||||||||||||
| Date: | August 9, 2023 | By: | /s/ CHARLES DADSWELL | ||||||||||||||
| Name: | Charles Dadswell | ||||||||||||||||
| Title: | Interim Chief Executive Officer, General Counsel and Secretary | ||||||||||||||||
Exhibit Index
| Exhibit Number | Description | |||||||
Illumina, Inc. Press Release, dated August 9, 2023 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
Exhibit 99.1
Dr. Steven Barnard Appointed Chief Technology Officer
SAN DIEGO, August 9, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina’s Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Dr. Alex Aravanis, who held the position of CTO will be departing Illumina to pursue another opportunity outside of the company.
Dr. Barnard joined Illumina in 1998 as the company’s first scientist and fourth employee, holding a variety of leadership positions within Illumina’s R&D organization throughout his distinguished 25-year tenure. Through critical roles in research and technology development, Barnard contributed significantly to maturing Illumina’s foundational science technologies including synthetic chemistry, protein engineering, surface science, assay research and nanofabrication. He holds more than 100 patents globally and has been published in diverse, industry-leading scientific journals, such as Analytical Chemistry, Nature, Science, and Genome Research, to name a few.
As Vice President and Head of Global Advanced Science, Dr. Barnard played an integral role in advancing Illumina’s industry-leading products, including the launch of the revolutionary NovaSeq XTM series. His profound understanding of Illumina’s core technologies will allow him to step into this role and continue to improve R&D productivity and efficiency, as well as drive shareholder value.
“Steve is the consummate innovator, leading many of Illumina’s most important technical development projects over the last 25 years. He brings expansive institutional knowledge of our entire technology portfolio and will help Illumina continue to deliver on its important mission.” said Charles Dadswell, Interim Chief Executive Officer at Illumina. “I’d also like to thank Alex for his leadership, advancing our industry-leading innovations, and wish him every success in the future.”
Barnard earned his Ph.D. in chemistry from Tufts University under the mentorship of Illumina’s scientific founder, Dr. David Walt, and holds a bachelor’s degree in chemistry from Connecticut College.
“I am incredibly honored and excited to assume this new role at Illumina,” Dr. Barnard said. “I have seen firsthand what the dedicated people of Illumina can do to further our mission to improve human health and save lives. I’m thrilled to continue to work beside them in this new role as we continue to focus on our core technologies to unlock the power of the genome.”
On top of his countless scientific accomplishments, Barnard was instrumental in originating the iHope Program, launched by Illumina in partnership with Rady Children’s Hospital to make clinical whole-genome sequencing accessible to children facing rare and undiagnosed genetic diseases.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
David McAlpine
347-327-1336
PR@illumina.com